(Natural News) Companies that sell colloidal silver, which could provide protection against infection with the Wuhan coronavirus (COVID-19), now face possible reprimand from the United States Food and Drug Administration (FDA) for selling "fraudulent products."
The federal agency, which only considers pharmaceuticals to possess any medical benefits, says it recently issued warning letters to multiple firms instructing them to stop suggesting that colloidal silver can in any way help prevent, treat, mitigate, diagnose or cure the Wuhan coronavirus (COVID-19).
Instead of focusing on FDA-approved pharmaceuticals, which maim and kill hundreds of thousands of Americans every year, the FDA has instead indicated that it will be "actively monitoring" companies that sell colloidal silver to ensure that they're not trying to help people avoid infection using this natural alternative.
"The FDA is exercising its authority to protect consumers from firms selling unapproved products and making false or misleading claims, including, by pursuing warning letters, seizures, or injunctions against products and firms or individuals that violate the law," the agency further indicated in an announcement on its "Health Fraud Scams" website.
In order to make way for an eventual Wuhan coronavirus (COVID-19) vaccine, the FDA is trying to clear out natural things like colloidal silver, vitamin C, zinc, and quinone that threaten to expose the inevitable jab "solution" as unnecessary, and thus fraudulent.
The colloidal silver companies targeted by the FDA as part of its crackdown include:
• JRB Enterprise Group Inc. DBA Anti-Aging Bed
• Halosense Inc.
• Bioactive C60/FullerLifeC60 LLC
• Xephyr LLC dba N-ergetics
• GuruNanda, LLC
• Quinessence Aromatherapy Ltd
• Vivify Holistic Clinic
• Colloidal Vitality LLC
• The Jim Baker Show
• Herbal Amy Inc.
Listen below to The Health Ranger Report as Mike Adams, the Health Ranger, talks about how people are already fleeing big cities to get away from what's to come with the Wuhan coronavirus (COVID-19) crisis: